1. Home
  2. SLNO vs BCO Comparison

SLNO vs BCO Comparison

Compare SLNO & BCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLNO
  • BCO
  • Stock Information
  • Founded
  • SLNO 1999
  • BCO 1859
  • Country
  • SLNO United States
  • BCO United States
  • Employees
  • SLNO N/A
  • BCO N/A
  • Industry
  • SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • BCO Oil Refining/Marketing
  • Sector
  • SLNO Health Care
  • BCO Consumer Discretionary
  • Exchange
  • SLNO Nasdaq
  • BCO Nasdaq
  • Market Cap
  • SLNO 3.2B
  • BCO 3.7B
  • IPO Year
  • SLNO 2014
  • BCO N/A
  • Fundamental
  • Price
  • SLNO $74.47
  • BCO $81.15
  • Analyst Decision
  • SLNO Strong Buy
  • BCO Strong Buy
  • Analyst Count
  • SLNO 9
  • BCO 1
  • Target Price
  • SLNO $103.33
  • BCO $138.00
  • AVG Volume (30 Days)
  • SLNO 744.8K
  • BCO 378.0K
  • Earning Date
  • SLNO 05-07-2025
  • BCO 05-12-2025
  • Dividend Yield
  • SLNO N/A
  • BCO 1.24%
  • EPS Growth
  • SLNO N/A
  • BCO 41.25
  • EPS
  • SLNO N/A
  • BCO 3.72
  • Revenue
  • SLNO N/A
  • BCO $5,022,500,000.00
  • Revenue This Year
  • SLNO N/A
  • BCO $3.91
  • Revenue Next Year
  • SLNO N/A
  • BCO $4.45
  • P/E Ratio
  • SLNO N/A
  • BCO $22.23
  • Revenue Growth
  • SLNO N/A
  • BCO 1.97
  • 52 Week Low
  • SLNO $36.93
  • BCO $80.21
  • 52 Week High
  • SLNO $80.99
  • BCO $115.91
  • Technical
  • Relative Strength Index (RSI)
  • SLNO 50.25
  • BCO 34.68
  • Support Level
  • SLNO $72.59
  • BCO $81.58
  • Resistance Level
  • SLNO $78.32
  • BCO $84.70
  • Average True Range (ATR)
  • SLNO 2.70
  • BCO 1.88
  • MACD
  • SLNO -0.63
  • BCO -0.72
  • Stochastic Oscillator
  • SLNO 32.52
  • BCO 0.00

About SLNO Soleno Therapeutics Inc.

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

About BCO Brinks Company (The)

The Brink's Co is a provider of secure logistics and security solutions for cash and other valuables. Its segments include: North America segment includes operations in the U.S. and Canada, including the Brink's Global Services (BGS) line of business; Latin America segment consists operations in Latin American countries where it has an ownership interest, including the BGS line of business; Europe segment includes total operations in European countries that provide services outside of the BGS line of business; and Rest of World segment consists operations in the Middle East, Africa and Asia. It also includes total operations in European countries that provides BGS services and BGS activity in Latin American countries. It derives maximum revenue from North America segment.

Share on Social Networks: